Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Study of Durvalumab Alone or with Tremelimumab in Metastatic Pancreatic Ductal Adenocarcinoma
2015-002001-11Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Sep 2015
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in pancreatic adenocarcinoma (PDAC) comparing Durvalumab monotherapy, Durvalumab + tremelimumab and Standard-of-care chemotherapy (3 arms). Primary endpoint: Objective response rate. Started Sep 2015; status: completed.
02
Drugs
durvalumabtremelimumab
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on 2015-002001-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002001-11.